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Abstract
Summary No clinically important pharmacokinetic interference
of alendronate occurred between a new effervescent formulation
of alendronate and levothyroxine when coadministered. The
combination does not materially affect levothyroxine absorption.
Introduction Concurrent treatment of osteoporosis with
alendronate (Aln) and hypothyroidism with levothyroxine
(LT4) may be problematic because both drugs are to be taken
separately after fasting overnight. The primary objective was
to assess pharmacokinetic interactions between a new effer-
vescent formulation of Aln (Aln-NEF) and LT4.
Methods A randomized, open-label, 3-way crossover study
was conducted in 30 healthy adults (15 women). Subjects
were dosed 3 times, separated by 35 days, after overnight
fasts, with Aln-NEF alone (70 mg), LT4 alone (600 μg), or
Aln-NEF and LT4 concurrently. Samples were analyzed for
plasma Aln and serum LT4. Pharmacokinetic drug-drug inter-
action was assessed using 90% confidence intervals (CIs) for
the test/reference ratio of the geometric means for area under
the concentration-time curve from time zero to last
measureable time point (AUC0-t) and maximum concentration
(Cmax). Results were compared to the default no-effect bound-
aries of 80 to 125% for the ratio Aln-NEF and LT4
concurrently/Aln-NEF alone and the ratio Aln-NEF and LT4
concurrently/LT4 alone.
Results Geometric mean ratios (Aln-NEF with LT4/Aln-NEF
alone) were 0.927 (90% CI 0.795–1.081) for AUC0–8 and
0.912 (90% CI 0.773–1.077) for Cmax, demonstrating LT4
does not appreciably affect the pharmacokinetics of Aln.
Geometric mean ratios (LT4 with Aln-NEF/LT4 alone) were
1.049 (90% CI 0.983–1.119) for AUC0–48 and 1.075 (90% CI
1.006–1.148) for Cmax, demonstrating LT4 is bioequivalent
between the 2 treatments. Coadministration of Aln-NEF and
LT4 was well tolerated.
Conclusions There was no clinically important pharmacoki-
netic interference between the Aln-NEF formulation and LT4.
Aln-NEF does not materially affect LT4 absorption.
Keywords Alendronate .Bisphosphonate .Druginteraction .
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Introduction
Alendronate (Aln) is a widely used bisphosphonate for treat-
ment of osteoporosis in postmenopausal women and for treat-
ment to increase bone mass in men with osteoporosis [1, 2]. A
recently approved new effervescent formulation of Aln (Aln-
NEF) is given onceweekly. Aswith all Aln formulations, Aln-
NEF must be taken after an overnight fast at least 30 min
before the first food, beverage, or medication of the day be-
cause food decreases the absorption. The dosing instructions
for Aln-NEF must be followed in order to assure adequate
drug absorption and to minimize the risk of esophageal ad-
verse reactions [3].
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It may be challenging for a patient to take more than 1
prescribed medication in the fasted state. A search was per-
formed to identify oral drugs taken in the fasted state [4]. The
search identified six drugs that are to be taken exclusively
under overnight fasting conditions: three bisphosphonates
(Aln alone and in combination with cholecalciferol,
ibandronate, and risedronate), levothyroxine (LT4), and
linaclotide (a guanylate cyclase-C agonist used to treat chronic
constipation). Many patients treated for osteoporosis may re-
quire thyroid hormone replacement. A study conducted in
older adults (57 to 85 years of age) to estimate potential major
drug-drug interactions of medications and supplements using
a household interview documented the use of these medica-
tions [5]. Aln and LT4 were the 15th and 4th most commonly
used drugs, respectively. It was estimated that 4.5% of older
adults in the USA take Aln and 12.4% take LT4 [5].
Pharmacokinetics
According to the approved product labeling, Aln has low
oral bioavailability, and there is a well-documented de-
crease in its absorption when taken with food [3].
Clinical studies with Aln oral tablets (Fosamax®) showed
the mean oral bioavailability relative to intravenous ad-
ministration of Aln in women was 0.64% (for doses rang-
ing from 5 to 70 mg) and 0.59% (for a dose of 10 mg) in
men when administered after an overnight fast and 2 h
before breakfast [3]. Aln was effective when administered
at least 30 min before breakfast in studies of the treatment
and prevention of osteoporosis [3].
Aln administration with coffee or orange juice reduced bio-
availability by approximately 60% [3].
Aln-NEF has also demonstrated a food interaction. A study
evaluating the effect of food on absorption showed Aln bio-
availability to be decreased by approximately 50% when Aln-
NEF was administered 15 min before a standardized breakfast
to 119 healthy women compared to Aln-NEF administration
followed by a 4-h fast [3].
LT4 is administered as a single daily dose, preferably one
half to 1 h before breakfast and should be taken at least 4 h
apart from drugs that are known to interfere with its absorp-
tion. LT4 is administered in the fasted state because certain
foods alter its bioavailability. Gastrointestinal tract absorption
of LT4 ranges from 40 to 80% and is increased by fasting and
decreased by certain foods. LT4 has a narrow therapeutic in-
dex. Careful dosage titration is necessary in order to avoid the
consequences of over- or under-treatment. Many drugs inter-
act with LT4 necessitating adjustments in dosing to maintain
an optimal therapeutic response; however, bisphosphonates
including Aln are not listed as interacting drugs in the LT4
prescribing information [6].
Evaluation of potential interaction
Potential interaction between LT4 and Aln could be due to
chemical reaction, interaction of the excipients in the formu-
lations, effects on the metabolism of the drugs, effects on
protein binding, effects on renal excretion, and effects on
pharmacodynamics.
Neither LT4 nor Aln possesses reactive substituents and
both are negatively charged; therefore, they would not be ex-
pected to interact chemically when ingested together.
Interference from excipients in the formulations is unlikely.
The LT4 tablets used in this study do not contain materials
known to interfere with Aln absorption in sufficient quantity
to be of concern, and the Aln-NEF formulation does not con-
tain any of the materials known to decrease LT4 absorption [3,
6]. Because Aln is not metabolized, it is not expected to affect
metabolizing enzymes and the metabolism of other drugs in-
cluding LT4 [6]. Other potential clinically important pharma-
cokinetic interactions involving protein binding and renal ex-
cretion are also considered unlikely due to the small amounts
of the two drugs dosed and/or absorbed [3, 6]. Any interfer-
ence between Aln-NEF and LT4 would likely be related to
interference in absorption.
Study design considerations
The primary objective was to evaluate the pharmacokinetic
interaction between Aln-NEF and LT4. Evaluation of the safe-
ty and tolerability of coadministration of Aln-NEF and LT4
was a secondary objective. The design of the Aln and LT4
study is complicated because Aln is poorly absorbed and cir-
culating levels are low. Furthermore, in order to raise LT4
levels above the endogenous background in normal subjects
to allow measurement, several times a normal dose of LT4
must be given, and the washout period for LT4 is long
(35 days). The dose administered in this study is a multiple
of the highest dose of LT4 marketed in keeping with FDA
guidance on LT4 tablets for in vivo bioavailability studies.
The use of a large dose (600 μg) of Synthroid in this study
is based on the Synthroid application for marketing approval
to FDA (NDA 21-402). It was established that two 300-μg
tablets were bioequivalent to a 600-μg oral solution [7]. The
Synthroid application also showed proportionality between
50-, 100-, and 300-μg Synthroid tablets. The approved prod-
uct label for Synthroid states that the excipients are the same
for each strength [6]. In order to deliver 600 μg of LT4 while
simulating the clinical administration of only one or two tab-
lets, the use of two 300-μg tablets was chosen for this study to
minimize the risk of any artifact that might be introduced by a
large number of tablets.
The sample size was based on FDA guidelines [8] and not
on statistical considerations. FDA’s Division of Bone,
Reproductive, and Urologic Products was consulted
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This study was conducted in 15 men and 15 nonpregnant,
nonlactating women, aged 18 to 45 years, who were healthy
based on a complete physical examination and medical histo-
ry, vital signs, electrocardiography (ECG), and clinical labo-
ratory tests. Subjects were not enrolled if they had a history of
thyroid disorders, esophageal disorders, and/or swallowing
disorders; had participated in another clinical trial with an
investigational drug within 30 days before inclusion in this
trial; or had taken any prescription or non-prescription drugs
within the 2 weeks preceding the study; if they had smoked,
chewed tobacco, or used nicotine-containing products within
the past 12months; or had consumed alcohol within 24 h prior
to screening. Subjects had to be able to sit or stand upright for
30 min. A number of restrictions were imposed on the sub-
jects, including abstinence from alcohol, caffeine-containing
beverages, tobacco (or nicotine-containing products), and
highly spiced foods for the duration of the study. On the day
of administration, the subjects were not allowed to eat any
food other than that provided.
All subjects gave written informed consent. The study was
approved by Chesapeake Institutional Review Board; it was
conducted in compliance with the good clinical practice and
ethical standards for human experimentation and in accor-
dance with applicable regulatory requirements. The study
was conducted between December 2013 and March 2014 at
Celerion, Neptune, NJ, and was sponsored by Mission
Pharmacal Company.
Study design
This was a randomized, single-center, open-label, 3-way
crossover study in healthy men and women. Subjects
received 3 treatments in random sequence. There was
a 35-day washout following the first 2 study periods.
Discharge from the study occurred 48 h after the third
study period.
Study drugs were administered to subjects after a 12-h
overnight fast. Subjects received either 1 dose of Aln-NEF
70 mg effervescent tablet (Binosto®, Mission Pharmacal
Company) dissolved in 4 oz water, 1 dose of LT4 600 μg
(2 × 300 μg Synthroid®, AbbVie Inc.) tablets with 4 oz water,
or concomitantly 1 dose of LT4 600 μg (2 × 300 μg) tablets
with 1 dose of Aln-NEF 70 mg dissolved in 4 oz water, in a
crossover design. According to the Aln-NEF label, the phar-
macy waited at least 5 min after the effervescence stopped and
stirred the solution for approximately 10 s prior to providing
Aln-NEF to the subjects. The subjects avoided lying down
until after a standardized meal was served 30 min following
dosing. Each study dose was administered with the subject in
a seated position. Dosing occurred between 8:00 AM and
9:00 AM. The study design is shown in Fig. 1.
Safety and tolerability assessment
Medical history and complete physical examinations were
conducted during screening; an abbreviated physical exami-
nation was performed at discharge. Blood and urine samples
were collected for routine laboratory tests at screening, during
study periods, and at discharge. ECGs were obtained during
screening and at discharge. Vital signs were monitored at
screening and each day when the subjects were in-house.
Subjects were continually observed and questioned during
study periods for possible adverse events.
Blood sampling times and bioanalytical methods
Venous blood samples for determination of Aln plasma con-
centrations were collected prior to (0 h) and at 0.25, 0.5, 0.75,
1, 1.5, 2, 3, 4, 5, 6, 7, and 8 h post-dose. The sample collection
times for Aln analysis were based on a study by Yun, et al.,
who measured alendronate in plasma following administra-
tion of alendronate sodium tablets [9]. For determination of
LT4 serum concentrations, venous blood samples were col-
lected at baseline (0.5, 0.25, and 0 h prior to dose) and at 0.5,
1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 18, 24, and 48 h post-dose.
Sample collection times for LT4 were those specified in the
FDA guidance on LT4 tablets in vivo pharmacokinetic and
bioavailability studies [8]. When both study drugs were ad-
ministered concurrently, the sample collection and analysis
procedures for each study drug were followed. Plasma and
serum samples were frozen at −70 °C and shipped on dry
ice to the analytical facility.
Aln plasma concentrations were determined using a vali-
dated liquid chromatography method with a tandem mass
spectrometric detection assay (LC-MS/MS). The assay had a
lower limit of quantification (LLOQ) of 50.0 pg/mL and a
linear range of 50.0–20,000 pg/mL. Precision and accuracy
were 0.5 to 8.4% and −3.3 to 8.4%, respectively. The selec-
tivity of the assay was demonstrated during method valida-
tion. No significant interference at the retention time and mass
transition of Aln or d6-Aln (internal standard) was observed
from endogenous components in any of the 6 human plasma
(EDTA) lots screened. The analytical method was developed
by Celerion, Lincoln, Nebraska, and validated according to
the standard operating procedures (SOPs) in effect at the lab-
oratory. These SOPs were based on the good laboratory prac-
tice principles described in 21 CFR Part 58 and the Guidance
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for Industry–Bioanalytical Method Validation (CDER,
May 2001).
Total (bound and free) LT4 and T3 serum concentrations
were determined using a Roche Diagnostics COBAS 6000, an
approved analyzer for diagnostic use in the USA. The method
is a validated electrochemiluminescence immunoassay.
The assay had an LLOQ of 1.91 μg/dL for LT4 and
48.05 ng/dL for T3. Linear ranges were 1.91–20.29 μg/dL
and 48.05–429.11 ng/dL for LT4 and T3, respectively.
Precision and accuracy were 4.04 to 5.03% and −7.98 to
−1.84%, respectively, for LT4 assay, and were 4.51 to 6.86%
and −4.06 to −2.51%, respectively, for T3 assay.
All samples were analyzed at Celerion, Lincoln, NE
Pharmacokinetic data analysis
The primary pharmacokinetic parameters were AUC0-t [area
under the concentration-time curve from time zero to last
measureable time point (t)] and Cmax (maximum concentra-
tion). Individual plasma concentrations of Aln and serum con-
centrations of LT4 and T3 were used to estimate pharmacoki-
netic parameters using non-compartmental analysis methods.
The Cmax and time to reach the maximum concentration
(Tmax) were the observed values. AUC0-twas calculated using
the linear trapezoidal method and extrapolated to infinity for
calculation of AUC0-∞ as follows:
AUC0−∞ ¼ AUC0−t þ AUCestkel
where Cest was the estimated concentration at the time of final
quantifiable sample and kel was the estimated rate constant at
terminal phase and was calculated as the negative of the slope
of the log:linear terminal portion of the concentration-time
curve using linear regression. The terminal half-life (T½) was
calculated as 0.693/kel.
Pharmacokinetic parameters of LT4 were calculated based
on both baseline-corrected and uncorrected serum concentra-
tions [10]. The average of the 3 serum concentrations at 0.5,
0.25, and 0 h prior to dosing was used as the baseline value
and was subtracted from the LT4 serum concentration at each
time point. Negative values after the correction were set to
zero.
Pharmacokinetic analysis was conducted using a validated
SAS® program.
Statistical analysis
The statistical analysis was carried out according to FDA
guidelines on the intent-to-treat dataset that included all sub-
jects for safety analysis and pharmacokinetic analysis.
Summary statistics including mean, standard deviation, medi-
an, minimum, and maximum were provided for the demo-
graphic data and pharmacokinetic parameters. An analysis of
variance (ANOVA) model, which included effects accounting
for sequence, period, treatment, and subject nested in se-
quence, was performed on the log-transformed pharmacoki-
netic parameters (Cmax and AUC) to determine the relative
bioavailability of a single dose of Aln-NEF with and without
concurrent LT4, and the relative bioavailability of a single
dose of LT4 with and without concurrent Aln-NEF. The geo-
metric mean ratio, the difference between the expected log
means, was estimated. Two-sided 90% confidence intervals
(CIs) for the geometric mean ratio were computed. The study
sample size was not based on a power calculation, but was
considered to be adequate to characterize a potential interac-
tion with sufficient accuracy based on previous similar studies
and FDA guidance on LT4 tablets in vivo pharmacokinetic
and bioavailability studies [8].
Results
Demographics and disposition of subjects
A total of 101 subjects were screened; 15 healthy men and 15
healthy women were enrolled. One subject withdrew after
taking coadministered Aln-NEF and LT4; another subject
was discontinued by the investigator for reasons other than
Fig. 1 Study design
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safety after taking Aln-NEF alone and LT4 alone. Therefore,
28 subjects completed all 3 treatment periods of the study with
no protocol deviations; 29 subjects received each of the 3
treatments. The mean (±SD) age was 29.6 (±5.8) years, and
mean (±SD) body mass index (BMI) was 24.53 ± 2.48. There
were 15 Caucasians, 14 African Americans, and 1 Pacific
Islander.
Safety
On study drug and for 48 h after study drug, the same low
proportion of subjects had adverse events following adminis-
tration of LT4 alone and Aln-NEF with LT4. No subjects
reported adverse events following Aln-NEF alone. There were
no serious adverse events, and no clinically important changes
or trends in vital signs, ECGs, or clinical laboratory tests with
any of the treatments. Most adverse events reported were mild
to moderate and not related to treatment.
Pharmacokinetic results
Because the results were the same for the intent-to-treat and
the per protocol analyses, only the intent-to-treat results are
discussed. Aln plasma concentrations versus time profiles il-
lustrate a rapid absorption phase after oral administration,
followed by a multi-exponential disposition, and were super-
imposable between the treatments (Fig. 2).
The extent of absorption of Aln, determined by the AUC0–8,
is similar between the treatments (18,097 pg·h/mL for Aln-NEF
alone, 17,784 pg·h/mL for Aln-NEF and LT4). Aln is eliminated
rapidly from plasma with a mean estimated T½ of 2.45 h after
administration of Aln-NEF alone and 2.36 h after Aln-NEF and
LT4 coadministration. This suggests a similar rate and extent of
Aln absorption following oral administration of Aln-NEF alone
and Aln-NEF with LT4 concurrently. Median Tmax values were
0.75 h after both treatments; mean (±SD)Cmax were 11.6 ± 6.07
vs. 11.9 ± 5.55 ng/mL and mean (±SD) AUC0-∞ were
18.6 ± 8.95 vs. 18.9 ± 7.64 ng·h/mL after concurrent compared
to single drug administration (Table 1).
The ANOVA for the ratio of Aln Cmax and AUC0–8 values
after concurrent administration compared to single adminis-
tration, using log-transformed data, are shown in Table 2 and
illustrated in Fig. 3. The geometric mean ratio [(Aln-NEF +
LT4)/Aln-NEF] was 0.91 (90% CI 0.77–1.08) for Cmax and
0.93 (90% CI 0.79–1.08) for AUC0–8. Although the lower
limit of the CIs for the mean ratios fell just below the usual
bioequivalence acceptance range of 0.80–1.25, the slight re-
duction in Aln exposure observed (approximately 9%) when
coadministered with LT4 was not considered clinically
important.
These results suggest that concurrent administration of Aln
with LT4 does not materially affect the pharmacokinetics of
Aln.
The serum LT4 mean concentration-time profiles are
shown in Fig. 3. There were no significant differences in se-
rum LT4 concentrations at each observed time point between
coadministration of Aln with LT4 and LT4 alone. Mean phar-
macokinetic parameters were similar between treatments
(Table 1).
The geometric mean ratios [(LT4 + Aln-NEF)/LT4] were
1.08 (90% CI 1.01–1.15) for Cmax and 1.05 (90% CI 0.98–
1.12) for AUC0–48 (Table 3). The CIs fell within the 0.8–1.25
bioequivalence range.
LT4 serum concentration rises rapidly from baseline,
followed by a slow decline. The mean Cmax values are similar
between LT4 alone (3.50 μg/dL) and Aln-NEF and LT4
(3.76 μg/dL). The extent of absorption, determined by
AUC0–48, is similar between treatments (95.40 μg·h/dL for
LT4 alone, 101.0 μg h/dL for Aln-NEF and LT4).
These results demonstrate that LT4 is bioequivalent when
coadministered with Aln compared to LT4 administered
alone; Aln does not affect the pharmacokinetics of LT4.
Discussion
Healthy male and female subjects were chosen as participants
for this study in compliance with FDA guidance for in vivo
Fig. 2 Aln plasma concentration-
time profiles (mean ± SE, linear
scale) Aln-NEF alone and Aln-
NEF and LT4 concurrently
(n = 29)
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pharmacokinetic and bioavailability studies using LT4 tablets.
Most patients administered alendronate are postmenopausal
women who are older than the subjects in this study.
Alendronate is also approved in the USA for treatment to
increase bone mass in men, so it was appropriate to include
men in this study. The reason for any potential interaction
between Aln and LT4 would be a physicochemical interaction
of the products within the intestinal lumen. The physicochem-
ical properties of the drugs are not a function of age and sex of
the patients.
Aln dosing instructions specify upright posture, and LT4
dosing instructions do not specify posture. Therefore, all sub-
jects were dosed in conformance with the Aln directions.
Subjects were treated consistently at each dosing/draw visit.
While there is some evidence that sustained standing versus
supine posture can affect LT4 levels [11] and there are no such
studies for Aln, the consistent seated position for this study
provides a systematic control for any such variation, while
remaining consistent with approved product labeling.
Bioanalytical methods used in the measurement of Aln
have been reported previously [12, 13]. Because absorbed
Aln disappears rapidly from systemic circulation (plasma T½
0.5 to 2 h after oral administration) and is renally excreted
rather than metabolized [14], the number of bioanalytical
methods for use with serum or plasma is limited [15].
Consequently, many pharmacokinetic studies have relied on
urine, rather than plasma, in the determination of Aln concen-
trations [16, 17]. To date, there are 2 studies that have deter-
mined plasma Aln concentrations for bioavailability and bio-
equivalence assessments of Aln tablets using a validated high-
performance liquid chromatography (HPLC) method with
fluorescence detection and LLOQs of 1 to 2 ng/mL [9, 18].
In the present study, a validated LC-MS/MSmethodwith high
sensitivity (LLOQ 50 pg/mL) and selectivity was used to de-
termine Aln plasma concentrations.
In the 2 previously published studies [9, 18], Aln tablets
were administered with 240 mL of water after an overnight
fast; a standardized meal was given at 4 h post-dose. In the
present study, Aln-NEF was dissolved in 4 oz (about 120 mL)
water for administration; a standardized meal was given
30 min after dosing. The Tmax and T½ values obtained in this
study were similar to those previously reported [9, 18]. Aln
plasma exposure values (Cmax and AUC0-∞) were slightly
lower, which may reflect differences in population studied,
bioanalytical method used, drug administration, or timing of
the first meal.
In the present study, there was no material pharmacokinetic
interaction between Aln and LT4 observed when Aln-NEF
and LT4 were coadministered. The 90% CIs for the geometric
mean ratio of Aln Cmax (0.77 to 1.08) and AUC0-∞ (0.79 to
Table 1 Aln and LT4 mean
(±SD) pharmacokinetic
parameters after oral
administration of a single dose of
70 mg Aln-NEF alone, 600 μg
LT4 alone, or 70 mg Aln-NEF
and 600 μg LT4 concurrently in
healthy subjects
Parameter Aln-NEF + LT4 (n = 29) Aln-NEF (n = 29) LT4 (n = 29)
Aln
Cmax (ng/mL) 11.6 (±6.07) 11.9 (±5.55) –
Tmax
a (h) 0.75 (0.5–1.0) 0.75 (0.5–1.0) –
AUC0–8 (ng·h/mL) 17.8 (±8.62) 18.1 (±7.43) –
AUC0-∞ (ng·h/mL) 18.6 (±8.95) 18.9 (±7.64) –
T½ (h) 2.36 (±0.51) 2.45 (±0.59) –
LT4
Cmax (μg/dL) 3.76 (±0.79) – 3.50 (±0.76)
Tmax
a (h) 3.0 (1.0–10.0) – 2.5 (1.0–12.0)
AUC0–48 (μg·h/dL) 101.0 (±21.8) – 95.4 (±24.7)
aMedian and range
Table 2 Relative geometric mean and ratio of Aln-NEF and LT4 concurrently to Aln-NEF alone for alendronate
Pharmacokinetic parameter (units) Estimated geometric meana Ratio of meansb 90% CI
Aln-NEF + LT4 (n = 29) Aln-NEF (n = 29) Lower limit Upper limit
Cmax (pg/mL) 9964 10,922 0.912 0.773 1.077
AUC0–8 (pg·h/mL) 15,576 16,798 0.927 0.795 1.081




1.08) contained 1, the lower bounds were near the bioequiva-
lence boundary of 0.8, and the upper bounds were within the
boundary of 1.25. The 90% CIs for the geometric mean ratio
of LT4 Cmax (1.01 to 1.15) and AUC0–48 (0.98 to 1.12) fell
within the 0.8 to 1.25 bioequivalence boundary. The variabil-
ity in Tmax was greater than anticipated. The reason for this
higher variability is unknown. Nevertheless, AUC values
were much tighter and are far more important. These results
are consistent with the prediction based on the known physi-
cochemical properties of Aln-NEF and LT4, and the pharma-
cokinetic characteristics of Aln and LT4.
Because LT4 is administered daily and Aln-NEF is admin-
istered once weekly, an increase of a few percent in LT4 ab-
sorption 1 day of the week would have no appreciable effect
on average LT4 levels. These results indicate that coadminis-
tration of LT4 with the specific Aln-NEF formulation tested is
feasible. The LT4 levels thereby achieved were bioequivalent
to those achieved in the same study subjects in the absence of
Aln. Of course, monitoring of thyroid function tests and ad-
justment of LT4 dosage, as needed, will remain essential in the
management of hypothyroidism. It would be appropriate to
perform laboratory reassessment of the patient’s thyroxine
status after 6 to 8 weeks of coadministration. The Aln levels
achieved in this study missed the formal boundary for deter-
mination of bioequivalence by less than 1%. In the clinical
trial (FIT) that established the anti-fracture efficacy of Aln, the
participants in the active treatment arm received 5 mg daily for
the first 2 years, followed by 10 mg daily for approximately
one more year [1]. In the extension of that study, (FLEX)
participants received either 5 or 10 mg daily or placebo. The
2 active arms produced similar results and were pooled [19]. It
seems clear that there is a much wider therapeutic window for
Aln treatment of osteoporosis than for LT4 treatment of hypo-
thyroidism. Therefore, no clinically important difference in
the efficacy of Aln would be expected to result from
coadministration.
For LT4, Cmax is marginally higher for the combined ad-
ministration group (CI for the ratio was 1.006–1.148). Of
course, in view of the long half-life of LT4, it is the AUC that
is of clinical importance. The upper limit of the confidence
interval for the ratio of AUCs was 1.119, and the mean ratio
was 1.049. Taking into account the weekly schedule of admin-
istration of Aln, and the usual daily administration schedule
for LT4, the effect on weekly AUC of LT4 would be less than
1% at the mean and less than 2% at the upper limit of the 90%
confidence interval.
Aln-NEF and LT4 were well tolerated when given alone or
concurrently administered in healthy subjects. There was no
significant pharmacokinetic interference between the Aln-
NEF formulation of Aln sodium and LT4. LT4 does not ma-
terially affect absorption of Aln when administered as Aln-
NEF. Whether the findings of this study that used Aln-NEF
apply to any other formulations of Aln is uncertain. A formal
interaction study would be necessary to evaluate each
Fig. 3 Total LT4 mean serum
concentration-time profiles
(baseline-corrected, mean ± SE,
linear scale) LT4 alone and Aln-
NEF and LT4 concurrently
(n = 29)
Table 3 Geometric mean and ratio of Aln-NEF and LT4 concurrently to LT4 alone for LT4
Pharmacokinetic parameter (units) Estimated geometric meana Ratio of meansb 90% CI
Aln-NEF + LT4 (n = 29) Aln-NEF (n = 29) Lower limit Upper limit
Cmax (μg/dL) 3.694 3.437 1.075 1.006 1.148
AUC0–48 (μg·h/dL) 97.457 92.931 1.049 0.983 1.119




formulation of Aln, available as either tablets for oral use or
oral solution, with LT4 as the formulations may vary in
composition.
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